Current Liabilities
Accrued Liabilities, Current
Vertex Pharmaceuticals Accrued Liabilities, Current increased by 0.4% to $2.98B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.1%, from $2.95B to $2.98B. Over 5 years (FY 2020 to FY 2025), Accrued Liabilities, Current shows an upward trend with a 16.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase may reflect growing operational scale or timing differences in payments, while a decrease suggests efficient settlement of short-term obligations.
Detailed definition
This represents obligations for expenses that have been incurred but not yet invoiced or paid by the end of the reportin...
Peer comparison
Standard operational metric across all industries; levels correlate with company size and payroll cycles.
Metric ID:
current_liabilities_accrued_liabilities_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.48B | $1.58B | $1.68B | $1.72B | $2.12B | $2.26B | $2.13B | $2.33B | $2.60B | $2.91B | $2.66B | $2.80B | $2.94B | $3.22B | $2.79B | $2.95B | $3.27B | $3.61B | $2.97B | $2.98B |
| QoQ Change | — | +6.9% | +5.9% | +2.5% | +23.2% | +6.8% | -6.1% | +9.4% | +11.7% | +11.9% | -8.7% | +5.3% | +5.2% | +9.5% | -13.4% | +5.9% | +10.8% | +10.5% | -17.8% | +0.4% |
| YoY Change | — | — | — | — | +43.0% | +42.9% | +26.7% | +35.2% | +22.6% | +28.4% | +24.9% | +20.2% | +13.2% | +10.7% | +5.0% | +5.6% | +11.2% | +12.2% | +6.5% | +1.1% |
Range$1.48B – $3.61B
CAGR+15.9%
Avg YoY Growth+19.3%
Median YoY Growth+16.7%
Accrued Liabilities, Current at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's accrued liabilities, current?
- Vertex Pharmaceuticals (VRTX) reported accrued liabilities, current of $2.98B in Q1 2026.
- How has Vertex Pharmaceuticals's accrued liabilities, current changed year-over-year?
- Vertex Pharmaceuticals's accrued liabilities, current increased by 1.1% year-over-year, from $2.95B to $2.98B.
- What is the long-term trend for Vertex Pharmaceuticals's accrued liabilities, current?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's accrued liabilities, current has grown at a 16.2% compound annual growth rate (CAGR), from $1.41B to $2.97B.
- What does accrued liabilities, current mean?
- Money owed for services or expenses that have been incurred but not yet paid.